UC San Diego Health

Changing the World Through Philanthropy: UC San Diego Raises $3.05 Billion as Campaign for UC San Diego Concludes

Retrieved on: 
Jeudi, juillet 14, 2022
Scripps Institution of Oceanography, Student, Multimedia, Empathy, Campaign, SVKM's NMIMS, Patient, Trustee, SAN, Jacobs Medical Center, Research, UC, UC San Diego Health, Compassion, University, Rady School of Management, Doctor of Philosophy, Cabinet, Renewable energy, Pharmaceutical industry, Oceanography

SAN DIEGO, July 14, 2022 /PRNewswire/ -- The University of California San Diego has reached the conclusion of its landmark Campaign for UC San Diego, raising a total of $3.05 billion in philanthropic support over a span of 10 years. The funds have spurred a significant campus transformation, increased access with scholarships and fellowships for the next generation of leaders and expanded the university's positive global impact with research that is addressing some of the world's most pressing concerns.

Key Points: 
  • Founded in 1960, UC San Diego is the nation's youngest university to reach a multibillion-dollar fundraising goal in a single campaign, raising $1 billion more than the original $2 billion goal.
  • More than 163,000 supporters designated charitable gifts and grants to over 450 different areas across campus, including UC San Diego Health and Scripps Institution of Oceanography.
  • Campaign for UC San Diego volunteer leadership played a critical role in the success of the Campaign.
  • In addition, more than 100 alumni and community members stepped up to lead this historic effort as members of the Campaign for UC San Diego Cabinet.

Teenager Severely Burned When Teacher Conducts Science Experiment - Launches Golf Foundation to Help Others Heal

Retrieved on: 
Lundi, juin 20, 2022
Science, UC San Diego Health, Hair, Hospital, Heal Family House, Injury, PGA, Health, Neck, RSVP, SAN, Mission, Glass, Life insurance, Golf

The event is open to the public and will include entertainment, refreshments, appetizers, and tours of the Bannister Family House.

Key Points: 
  • The event is open to the public and will include entertainment, refreshments, appetizers, and tours of the Bannister Family House.
  • The organization was founded by Priest James Rivera who suffered life-threatening burns while viewing a science experiment conducted by his 6th-grade teacher.
  • The experiment exploded in Priest's face, causing his left cheek, ears, neck, chest, eyelid, and hair to catch fire.
  • Realizing that his recovery and success was directly related to the therapeutic aspects of golf, the Priest James Foundation was founded.

Emergency Department Study Demonstrates Utility of MediPines AGM100 in Triaging COVID-19 Patients

Retrieved on: 
Jeudi, juin 16, 2022
Other Health, Other Science, Other Technology, Research, Insurance, Medical Devices, Infectious Diseases, Hospitals, Data Management, Professional Services, Science, Technology, Mobile, Wireless, Nursing, Cardiology, General Health, COVID-19, Health, Doctor of Philosophy, Triage, FDA, COVID-19, World, ATS, WHO, Method, UC San Diego Health, International Conference on Emerging Infectious Diseases, COPD, Gas, AUC, Hospital, American Thoracic Society, Physician, University, World Health Organization, ED, Receiver operating characteristic, UCSD, Medicine, Patient, University of California, San Diego Performance-Based Skills Assessment, Urinary tract infection, Conference, VO2 max, Risk, Pharmaceutical industry, Medical imaging, MD, COVID, ROC

The measurement of gas exchange impairment (known as Oxygen Deficit) helped physicians accurately determine the need for hospital admission and supplemental oxygen administration in the emergency department (ED).

Key Points: 
  • The measurement of gas exchange impairment (known as Oxygen Deficit) helped physicians accurately determine the need for hospital admission and supplemental oxygen administration in the emergency department (ED).
  • The data indicate that the AGM100 is useful for important hospital admission and supplemental oxygen administration decisions in COVID-19 patients.
  • Additionally, the authors found that the AGM100 is able to identify patients at risk prior to obvious clinical deterioration, in a non-invasive, point-of-care fashion.
  • This study demonstrates that the AGM100 has utility for physicians on the front lines of medicine to combat the rising chronic respiratory disease burden.

Brendan Kremer Joins Shadowbox Board of Directors

Retrieved on: 
Mercredi, juin 1, 2022
UC San Diego Health, UCSD, Moores Cancer Center, COO, Substance Abuse and Mental Health Services Administration, AI, Huntington Hospital, UC, Solution, Multimedia, University, Children's Hospital Los Angeles, Health, Patient, MHA, Public administration, BSPA, SAN, University of California, San Diego, Automation, Tenet Healthcare, Pharmaceutical industry, Online shopping, Hospital, Science, Shadowbox

SAN DIEGO, June 1, 2022 /PRNewswire/ -- Shadowbox, a leading innovator in healthcare automation solutions, is excited to announce the addition of Brendan Kremer, Chief Operating Officer of UC San Diego Health, to its board of directors. Brendan brings over 25 years of health system administration leadership experience to the Shadowbox board. As COO at UCSD Health, he is responsible for hospital and physician group operations for a $3 billion academic medical center, accountable for the clinical, financial, and operational performance of all clinical service lines as well as physician group and support service operations.

Key Points: 
  • SAN DIEGO, June 1, 2022 /PRNewswire/ -- Shadowbox, a leading innovator in healthcare automation solutions, is excited to announce the addition of Brendan Kremer, Chief Operating Officer of UC San Diego Health, to its board of directors.
  • Brendan brings over 25 years of health system administration leadership experience to the Shadowbox board.
  • -Brendan Kremer, COO UCSD Health
    "We are overjoyed to welcome Brendan to our board of directors.
  • "Shadowbox offers a unique approach to solving one of healthcare's biggest challenges," said Brendan Kremer.

Sunrise unveils ground-breaking home sleep apnea test at SLEEP 2022

Retrieved on: 
Mardi, mai 10, 2022
UC San Diego School of Medicine, Atrial fibrillation, Sleep, Raymond and Monique Martinot, Coronary artery disease, Stroke, Physician, Cardiovascular disease, Patient, Respiration (physiology), Sleep apnea, UC San Diego Health, Heart, NAMUR, Diagnosis, ABC, Comorbidity, Artificial intelligence, Polysomnography, Classification, Machine learning, Critical care, De novo, CEO, Technology, Research, Multimedia, Pharmaceutical industry, Sunrise

NAMUR, Belgium, May 10, 2022 /PRNewswire/ -- For the millions of people concerned they may have sleep apnea, a confirmed diagnosis can be a lengthy and expensive process. Sunrise, a Belgium-based sleep technology company has created a lightweight, easy to use, at-home sleep test that provides clinically accurate results within hours. The company will unveil the device at SLEEP 2022 in Charlotte, North Carolina June 4-8. Attendees can visit booth #146 to learn about the simplicity it provides to both patient and provider, and the comprehensive clinical insights provided by the new technology.   

Key Points: 
  • Sunrise , a Belgium-based sleep technology company has created a lightweight, easy to use, at-home sleep test that provides clinically accurate results within hours.
  • The company will unveil the device at SLEEP 2022 in Charlotte, North Carolina June 4-8.
  • Sunrise's at-home sleep test provides results within hours and will be unveiled in the U.S. at SLEEP 2022 in June.
  • About Sunrise: Founded in 2015 and based in Namur, Belgium, Sunrise aims to democratize access to care for sleep apnea syndrome.

Xalles Studio is Collaborating with the University of California San Diego to Assist Early Stage Technology Companies

Retrieved on: 
Lundi, mai 9, 2022
University of California, San Diego, University, OTC, IGE, Securities Exchange Act of 1934, Solution, Technology, Forward-looking statement, UC, Company, Securities Act of 1933, Uncertainty, Hotbed, TAM, U.S. Securities and Exchange Commission, Security (finance), Korea, UC San Diego Health, Acquisition, GLOBE, Invention, Terminology, OTC Markets Group, Video game

WASHINGTON, DC, May 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing innovative technology and financial services solutions, today announces that Xalles Studio has partnered with the Institute for the Global Entrepreneur (IGE) at the University of Calfornia San Diego (UC San Diego) Jacob School of Engineering (JSOE) to accelerate early-stage and startup technology companies.

Key Points: 
  • (OTC: XALL),afintechholdingcompanyprovidinginnovativetechnologyandfinancialservicessolutions, today announces that XallesStudiohaspartneredwiththeInstitutefortheGlobalEntrepreneur(IGE)atthe University of Calfornia San Diego (UCSanDiego)JacobSchoolofEngineering(JSOE)toaccelerate early-stage and startup technology companies.
  • XallesStudio,abusinessunitofXallesCapitalInc.,isanacceleratorprogramfocusedonhelpingearly-stage technologycompaniesreachtheirnextfinancialtransactionevent.XallesStudiolaunchedin2021withits initial 4 companyparticipantsandexpectsfastergrowthin2022throughitsnewlyformedrelationshipwith UC San Diego and IGE.
  • IGEcollaborateswithJacobsSchoolresearchcenters,partners,andresourcesacrosscampustohelpadvance innovative technologiesfromthelabtotheglobalmarketplace.Tothatend,IGEalsomaintainsastrongglobal networkthroughengagementswithuniversitycollaboratorsandindustrypartnersinJapanandKorea,and most recently, withsustainabilitypartnersinEurope.IGEstartupsrangefrommedicaltechnologiesto cleantech/energy.
  • For moreinformation,visitourwebsiteat www.xalles.com
    The InstitutefortheGlobalEntrepreneur(IGE) isaformalcollaborationbetweentheUCSan Diego Jacobs SchoolofEngineeringandRadySchoolofManagement,inspiringandtraining entrepreneurial leaders and catalyzing the translationofUCSanDiegotechnologiestofuelthe economy and benefit society.

Varian Highlights Comprehensive Cancer Care Portfolio at ESTRO 2022

Retrieved on: 
Jeudi, mai 5, 2022
Sola, Eclipse, European Society for Medical Oncology, Proton therapy, Thought, Proton, The Queen's Award for Enterprise: Innovation (Technology) (2002), Radiation, ARIA, Twitter, UC, Exhibition, Expert, Patient, UC San Diego Health, Siemens Healthineers, CT, CE, Diagnosis, Cancer, Medical examiner, Artificial intelligence, Connectivity, Afterload, Machine learning, Workflow, Radiation therapy, Database, Brachytherapy, Electron, Anatomy, Paradigm, Sale, Solution, Technology, Strathcona County, Freeman Hospital, Intelligence, Medical imaging, Medical device, Pharmaceutical industry, Varian, Ethos

PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark. The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship. In addition to driving speed and precision, these solutions seek to streamline workflows and empower cancer care teams to improve their clinical and operational performance and meet unique and evolving patient needs.

Key Points: 
  • Showcases Innovative Technologies and Services to Drive Personalization, Precision, and Connectivity Along the Radiotherapy Treatment Pathway
    PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark.
  • The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship.
  • Additional innovative solutions from Varian and Siemens Healthineers that will be showcased at ESTRO, include:
    ARIA oncology information system, which has been reimagined as a comprehensive cancer care management tool.
  • We are working to harness advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care.

Varian Highlights Comprehensive Cancer Care Portfolio at ESTRO 2022

Retrieved on: 
Jeudi, mai 5, 2022
Sola, Eclipse, European Society for Medical Oncology, Proton therapy, Thought, Proton, The Queen's Award for Enterprise: Innovation (Technology) (2002), Radiation, ARIA, Twitter, UC, Exhibition, Expert, Patient, UC San Diego Health, Siemens Healthineers, CT, CE, Diagnosis, Cancer, Medical examiner, Artificial intelligence, Connectivity, Afterload, Machine learning, Workflow, Radiation therapy, Database, Brachytherapy, Electron, Anatomy, Paradigm, Sale, Solution, Technology, Strathcona County, Freeman Hospital, Intelligence, Medical imaging, Medical device, Pharmaceutical industry, Varian, Ethos

PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark. The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship. In addition to driving speed and precision, these solutions seek to streamline workflows and empower cancer care teams to improve their clinical and operational performance and meet unique and evolving patient needs.

Key Points: 
  • Showcases Innovative Technologies and Services to Drive Personalization, Precision, and Connectivity Along the Radiotherapy Treatment Pathway
    PALO ALTO, Calif., May 5, 2022 /PRNewswire/ -- Varian, a Siemens Healthineers company, will be showcasing its comprehensive cancer care portfolio at the 2022 annual meeting of the European Society for Radiotherapy and Oncology (ESTRO), starting tomorrow in Copenhagen, Denmark.
  • The combined company's exhibit will highlight technologies that span the entire cancer care continuum, from screening and prevention, through diagnosis, therapy, and survivorship.
  • Additional innovative solutions from Varian and Siemens Healthineers that will be showcased at ESTRO, include:
    ARIA oncology information system, which has been reimagined as a comprehensive cancer care management tool.
  • We are working to harness advanced technologies like artificial intelligence, machine learning and data analytics to enhance cancer treatment and expand access to care.

Study Published in The American Journal of Obstetrics and Gynecology Shows The Mirvie RNA Platform is First to Predict Preterm Birth by Revealing the Underlying Biology of Each Pregnancy

Retrieved on: 
Mercredi, avril 13, 2022
Research, Women, Baby, Maternity, Genetics, Family, Biotechnology, General Health, Consumer, Health, Science, Mayfield (company), Mitchell, Pre-eclampsia, Perelman School of Medicine at the University of Pennsylvania, Woman, Preterm birth, Ectopic pregnancy, Research, Reproductive Sciences, American Journal, RNA, Khosla Ventures, Department, Machine learning, Patient, Mortality, Pregnancy, Professor, Principal, UC, University, Biology, Disease, Placenta, UC San Diego Health, American Journal of Obstetrics and Gynecology, Birth control, Vaccine, Obstetrics, Nature, Ephraim Mirvis, Gynaecology

The results demonstrate the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.

Key Points: 
  • The results demonstrate the Mirvie RNA platform is first to predict preterm birth by revealing the underlying biology of each pregnancy.
  • Specific RNA messages were able to predict preterm birth months before the occurrence of any symptoms.
  • This study shows the Mirvie RNA platform has the potential to transform how we detect, prevent, and treat preterm birth.
  • Early prediction of preterm birth with identification of the underlying biology creates new opportunities for pregnancy health.

Immunicom Announces Addition of Key Industry Leaders to Board of Directors

Retrieved on: 
Mardi, avril 12, 2022
Biotechnology, Health, Oncology, Medical Devices, Immunotherapy, University, CEO, SM, MIT, HR, CE marking, IPO, Faculty, University of Wisconsin–Madison, Audit committee, NASDAQ, Continuous positive airway pressure, Research, Terumo, SITC, CA, Doctor of Philosophy, CFO, Therapy, Housing, Communities and Local Government Committee, Patient, Goal, COO, Financial toxicity, Dialysis, Technology, Management development, ResMed, International Institute for Management Development, Company, Breast cancer, Sun Microsystems, Jacobs School of Engineering, Chemical engineering, Immune system, Society, UC, UC San Diego Health, NYSE, CPAP, Degenerative disease, Palo Alto Networks, Quality of life, FDA, Partnership, Medical device, Management, Engineering, Cancer

Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, announced that Dr. Peter Farrell and Michael E. Lehman have joined the Companys Board of Directors.

Key Points: 
  • Immunicom, Inc., a clinical-stage biotechnology company pioneering a first-of-its-kind technology platform for immuno-oncology, announced that Dr. Peter Farrell and Michael E. Lehman have joined the Companys Board of Directors.
  • The addition of the two members provides strong support to the Companys plans to commercialize its Immunopheresis platform in Europe.
  • It is an honor to have Dr. Peter Farrell and Mr. Michael Lehman join Immunicoms Board of Directors.
  • Immunicom is headquartered in San Diego, CA, with operations in Houston, TX, Philadelphia, PA, Krakow, Poland, and Istanbul, Turkey.